These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 12504820)

  • 1. Endothelin-1 induced proinflammatory markers in the myocardium and leukocytes of guinea-pigs: role of glycoprotein IIB/IIIA receptors.
    Molero L; Farré J; García-Mendez A; Jiménez Mateos-Caceres P; Carrasco Martín C; Millás I; Navarro F; Córdoba M; Casado S; López-Farré A
    Cardiovasc Res; 2003 Jan; 57(1):109-18. PubMed ID: 12504820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human thrombocytes are able to induce a myocardial dysfunction in the ischemic and reperfused guinea pig heart mediated by free radicals-role of the GPIIb/IIIa-blocker tirofiban.
    Seligmann C; Simsek Y; Schimmer M; Leitsch T; Bock A; Schultheiss HP
    Life Sci; 2002 Sep; 71(19):2319-29. PubMed ID: 12215379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
    Moriguchi A; Maeda M; Mihara K; Aoki T; Matsuoka N; Mutoh S
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):75-86. PubMed ID: 15678114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
    Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
    Thorac Cardiovasc Surg; 2006 Apr; 54(3):162-7. PubMed ID: 16639676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.
    Klinkhardt U; Graff J; Westrup D; Kirchmaier CM; Esslinger HU; Breddin HK; Harder S
    Br J Clin Pharmacol; 2001 Sep; 52(3):297-305. PubMed ID: 11560562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A; Voss R
    Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of platelets by the GPIIb/IIIa receptor antagonist Tirofiban reduces leukocyte-endothelial cell interaction in murine antigen-induced arthritis.
    Schmitt-Sody M; Metz P; Gottschalk O; Zysk S; Birkenmaier C; Goebl M; von Schulze Pellengahr C; Veihelmann A; Jansson V
    Inflamm Res; 2007 Oct; 56(10):414-20. PubMed ID: 18026698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardized ultrasound as a new method to induce platelet aggregation: evaluation, influence of lipoproteins and of glycoprotein IIb/IIIa antagonist tirofiban.
    Otto C; Baumann M; Schreiner T; Bartsch G; Borberg H; Schwandt P; Schmid-Schönbein H
    Eur J Ultrasound; 2001 Dec; 14(2-3):157-66. PubMed ID: 11704433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation.
    Ito H; Miyakoda G; Mori T
    Platelets; 2004 Aug; 15(5):293-301. PubMed ID: 15370100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet glycoprotein IIb/IIIa blockade with tirofiban: effect on aggregation caused by P256, an antibody to human IIb/IIIa receptors.
    Fisher I; Robinson P; Ritter JM
    Br J Clin Pharmacol; 1999 Aug; 48(2):197-9. PubMed ID: 10417496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
    Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
    Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of platelets aggregation in the process of ductus arteriosus closure of newborn pups].
    Ren Y; Gao X; Zhao D; Wang L; Huang D; Su M
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Nov; 34(11):1194-1199. PubMed ID: 36567565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
    Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
    Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.
    Hamilton SF; Miller MW; Thompson CA; Dale GL
    J Lab Clin Med; 2004 May; 143(5):320-6. PubMed ID: 15122176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons.
    Rao AK; Sun L; Hiramatsu Y; Gorman JH; Edmunds LH
    Thromb Haemost; 1999 Jul; 82(1):140-4. PubMed ID: 10456468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermic circulatory arrest.
    Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
    Thromb Haemost; 2005 Jul; 94(1):115-22. PubMed ID: 16113794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression.
    Steiner S; Seidinger D; Huber K; Kaun C; Minar E; Kopp CW
    Arterioscler Thromb Vasc Biol; 2003 Sep; 23(9):1697-702. PubMed ID: 12869353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.